“When the FDA says ‘we think you ought to consider’ something, that should not
be viewed as a suggestion, but as a mandate,” he explains. “Companies are
foolish if they don’t follow what the FDA has suggested.” A biotech takes on
significant and unnecessary risk if it doesn’t follow an FDA suggestion or
proactively address the FDA’s concerns. …
While genetic engineering is common in the food industry, a number of biotechs
are also using the science to produce hormones and antibodies that can be used
therapeutically. …
Fortunately, AGBIOS, a Canadian company with vast experience in public safety
and risk assessment of biotechnology products, has taken upon itself to deliver
an online repository of knowledge about these important organisms. …
AƦČ章Ɛ䁈Ɛ
This year’s report from the Attorney General’s Office showed that Vermont
doctors received $3.1 million in gifts and donations from the pharmaceutical and
medical industry — an increase of 33 percent over the previous year. …
Again, patients showed lower brain volume and larger fluid-filled spaces on MRI
scans, with no differences between those who began treatment either a few months
or more than 1,year after an initial period of psychosis. …
“Our new study is very promising because it suggests that we could alleviate
pain by targeting the cannabinoid receptor CB2 without causing the kinds of
side-effects we associate with people using cannabis itself.”
…
That’s bad news for the companies that make leading atypicals–Johnson & Johnson Risperdal, Eli Lilly (Zyprexa), Bristol-Myers Squibb (Abilify),Pfizer (Geodon), AstraZeneca(Seroquel). Prescription rates for these meds have enjoyed a
strong growth curve, increasing more than fivefold among children over the past
15 years. …
The lawsuit was filed for the Attorney General’s Office in the 1st Judicial
District Court in Santa Fe by a Houston civil litigation firm, Bailey Perrin
Bailey, which specializes in lawsuits over the new generation of antipsychotic
drugs known as atypical antipsychotics. …
“They are interested in pharmacogenetic purposes to do case control studies of
adverse drug reactions,” said John Novembre, a co-author of the study published
in Nature. …
the public doesn’t trust pharma to share adverse info on their meds, further undermining that faith–and hurting
pharma’s rep. …